News
ASCO 2025: Safety and Pharmacokinetics of Mevrometostat in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (UroToday.com) The 2025 American Society of ...
ASCO GU 2022 results of a phase 1/2 study examining the role of ARV-110 in metastatic castration-resistant prostate cancer (mCRPC), novel AR protein degrade ARV-110 demonstrates clinical activity in a ...
Meeting Abstract: 2020 ASCO Annual Meeting I. Free access. Breast Cancer—Metastatic. May 25, 2020. Share on. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback